Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Zhejiang Jiuzhou Pharmaceutical Co., Ltd (603456.SS)
Taizhou, CN
Zhejiang Jiuzhou Pharmaceutical Co., Ltd, a company established in 1973 and operating from its headquarters in Taizhou, China, specializes in the production and global supply of active pharmaceutical ingredients (APIs) and their chemical precursors. Its extensive product catalog includes APIs designed for a wide range of therapeutic applications, encompassing treatments for central nervous system disorders (such as anti-depressants and Parkinson's disease), various infectious ailments (including antiviral, general anti-infection, and specific respiratory anti-infection agents), diabetes management, non-steroidal drugs, oncological therapies, Hepatitis C, and cardiovascular conditions. Furthermore, beyond its pharmaceutical focus, the company also furnishes specialized asymmetric catalysts and crucial materials utilized in lithium-ion batteries.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+6.7% Q1'26: -19.4% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+21.5% ★ Q1'26: -32.1% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+19.0% ★ Q1'26: -1.3% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+16.9% ★ Q1'26: +18.4% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+10.1% ★ Q1'26: +9.0% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%-0.9% ★ Q1'26: +1.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.04× ★ Q1'26: 0.11× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 4 Rev. Ana. 5 EPS Ana. |
Dec 2027 3 Rev. Ana. 4 EPS Ana. |
Dec 2028 1 Rev. Ana. 3 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.44B
est: 1.60B (-9.9%)
|
1.65B
est: 1.54B (+7.1%)
|
1.72B
est: 1.80B (-4.7%)
|
1.86B
est: 1.89B (-1.5%)
|
2.02B
est: 2.02B (+0.1%)
|
2.65B
est: 2.70B (-2.1%)
|
4.06B
est: 4.03B (+0.8%)
|
5.45B
est: 5.56B (-2.0%)
|
5.52B
est: 5.03B (+9.7%)
|
5.16B
est: 5.21B (-1.0%)
|
5.51B
est: 5.51B (0.0%)
|
5.59B
5.40B – 5.79B
+1.4% YoY
|
5.73B
5.41B – 5.88B
+2.5% YoY
|
5.86B
5.60B – 6.05B
+2.3% YoY
|
| EBITDA |
292.52M
est: 402.91M (-27.4%)
|
254.86M
est: 387.59M (-34.2%)
|
354.55M
est: 452.88M (-21.7%)
|
389.31M
est: 474.71M (-18.0%)
|
481.71M
est: 506.18M (-4.8%)
|
718.90M
est: 679.10M (+5.9%)
|
1.02B
est: 1.01B (+0.5%)
|
1.37B
est: 1.40B (-1.9%)
|
1.48B
est: 1.26B (+17.0%)
|
1.11B
est: 1.31B (-15.2%)
|
1.35B
est: 1.38B (-2.3%)
|
1.40B
1.36B – 1.46B
+1.4% YoY
|
1.44B
1.36B – 1.48B
+2.5% YoY
|
1.47B
1.41B – 1.52B
+2.3% YoY
|
| EBIT |
183.14M
est: 282.81M (-35.2%)
|
102.19M
est: 272.05M (-62.4%)
|
186.86M
est: 317.88M (-41.2%)
|
213.76M
est: 333.20M (-35.8%)
|
290.78M
est: 355.29M (-18.2%)
|
466.58M
est: 476.67M (-2.1%)
|
725.97M
est: 710.75M (+2.1%)
|
1.03B
est: 979.61M (+4.7%)
|
1.10B
est: 887.40M (+24.3%)
|
715.31M
est: 918.71M (-22.1%)
|
929.58M
est: 971.32M (-4.3%)
|
984.72M
951.60M – 1.02B
+1.4% YoY
|
1.01B
954.35M – 1.04B
+2.5% YoY
|
1.03B
987.10M – 1.07B
+2.3% YoY
|
| Net Income |
200.08M
est: 241.99M (-17.3%)
|
111.48M
est: 169.64M (-34.3%)
|
147.61M
est: 184.61M (-20.0%)
|
157.15M
est: 224.53M (-30.0%)
|
237.79M
est: 287.39M (-17.3%)
|
380.58M
est: 417.62M (-8.9%)
|
633.90M
est: 686.41M (-7.7%)
|
921.17M
est: 965.46M (-4.6%)
|
1.03B
est: 886.36M (+16.6%)
|
606.10M
est: 891.15M (-32.0%)
|
730.07M
est: 730.22M (0.0%)
|
843.44M
764.15M – 922.73M
+15.5% YoY
|
912.52M
774.04M – 1.05B
+8.2% YoY
|
960.97M
905.63M – 1.00B
+5.3% YoY
|
| SGA |
263.72M
est: 162.13M (+62.7%)
|
276.38M
est: 155.96M (+77.2%)
|
219.19M
est: 182.23M (+20.3%)
|
266.75M
est: 191.01M (+39.6%)
|
289.01M
est: 203.68M (+41.9%)
|
340.13M
est: 273.26M (+24.5%)
|
383.42M
est: 407.45M (-5.9%)
|
480.09M
est: 561.58M (-14.5%)
|
524.15M
est: 508.72M (+3.0%)
|
513.31M
est: 526.67M (-2.5%)
|
120.08M
est: 556.83M (-78.4%)
|
564.51M
545.52M – 585.48M
+1.4% YoY
|
578.66M
547.10M – 594.75M
+2.5% YoY
|
592.10M
565.87M – 611.28M
+2.3% YoY
|
| EPS |
0.25
est: 0.27 (-7.2%)
|
0.14
est: 0.19 (-25.9%)
|
0.19
est: 0.21 (-7.6%)
|
0.20
est: 0.25 (-20.0%)
|
0.30
est: 0.32 (-7.5%)
|
0.47
est: 0.47 (+1.9%)
|
0.77
est: 0.76 (+0.7%)
|
1.11
est: 1.08 (+3.3%)
|
1.16
est: 0.99 (+17.1%)
|
0.68
est: 1.00 (-32.5%)
|
0.82
est: 0.82 (+0.0%)
|
0.96
0.85 – 1.03
+17.1% YoY
|
1.02
0.86 – 1.17
+6.3% YoY
|
1.07
1.01 – 1.12
+4.9% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-04-24 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-23 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-22 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-21 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-20 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-17 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-16 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Franklin FTSE China ETF FLCH | 0.01% | 14.4K | 0.19% |
| 2 | Franklin FTSE China UCITS ETF FLXC.L | 0.00% | 60.7K | 0.19% |
| 3 | Dimensional - Emerging Markets Value ETF DFEV | 0.00% | 74.0K | 0.46% |
| 4 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 293.7K | 0.39% |
| 5 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 127.0K | 0.29% |
| 6 | Schwab Emerging Markets Equity ETF SCHE | 0.00% | 160.6K | 0.06% |
| 7 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 13.3K | 0.48% |
| 8 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 30.1K | 0.26% |
| 9 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 1.48M | 0.06% |
| 10 | Vanguard FTSE Emerging Markets UCITS ETF (USD) Distributing VDEM.L | 0.00% | 38.3K | 0.17% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| An Wu | Accounting Supervisor | — | — |
| Gong Chen | Vice President | — | male |
| Huilu Lin | Vice President, Secretary of the Board of Directors & Director | — | male |
| Minxia Huang | Vice President | — | female |
| Nonggang Yang | Vice President | — | male |
| Yi Jiang Mei | President & Director | — | male |
| Yuanqiang Li | VP & Director | — | — |
| Yujie Sha | VP, Financial Director & Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 603456.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
